Roche (ROG) Given a CHF 275 Price Target at Bank of America

Bank of America set a CHF 275 price objective on Roche (VTX:ROG) in a research report report published on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other brokerages have also recently issued reports on ROG. Morgan Stanley set a CHF 260 price target on shares of Roche and gave the company a neutral rating in a research report on Friday, December 1st. Berenberg Bank set a CHF 273 price objective on shares of Roche and gave the stock a buy rating in a research report on Tuesday, August 15th. Goldman Sachs Group set a CHF 335 price target on shares of Roche and gave the stock a buy rating in a report on Tuesday, August 8th. J P Morgan Chase & Co restated a buy rating on shares of Roche in a report on Monday, October 2nd. Finally, Sanford C. Bernstein set a CHF 262 price objective on shares of Roche and gave the company a buy rating in a research note on Friday, December 1st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company’s stock. Roche currently has a consensus rating of Hold and an average target price of CHF 261.32.

Shares of Roche (VTX ROG) traded down CHF 5 during midday trading on Wednesday, reaching CHF 242.20. 2,290,000 shares of the company traded hands, compared to its average volume of 1,690,000. Roche has a fifty-two week low of CHF 219.10 and a fifty-two week high of CHF 273.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply